Friday 27 January 2017

Single-use Bioreactors Market Outlook to 2024 Latest Industry Forecast Report

Global Single-use Bioreactors Market: Overview
The use of single-use bioreactors across the global pharmaceutical industry has significantly increased since inception roughly two decades back. The market for these disposable bioreactors continues to tread along a healthy growth path as pharmaceutical companies begin to understand the immense flexibility and several other advantages associated with their use. For multi-drug producing pharmaceutical units, especially, single-use bioreactors mitigate the risk of cross-contamination and save significant time that is otherwise spent for cleaning and clearance validation to assure that no compounds are carried over from prior batches.
By lowering down the costs involved in cleaning and sterilizing bioreactors and increasing the operational flexibility of the entire drug manufacturing process, the use of single-use bioreactors leads to reduced capital expenditure costs. Owing to these factors, the preference for single-use bioreactors has significantly increased over the conventional stainless steel reactors in the past years.
An increasingly rising number of pharmaceutical companies are presently preferring the use of disposables for applications such as filtration, media preparation, purification, cell harvesting, virus inactivation, and buffer preparation. In the next few years, single-use bioreactors will play a central role in the pharmaceutical industry, supporting the need for the rapid development of novel drug varieties to tackle the vast array of diseases that are presently untreated or are becoming increasingly prevalent.
Global Single-use Bioreactors Market: Scope of the Report
This report on the global market for single-use bioreactors presents a thorough overview of the market’s present state and a forecast regarding the future growth prospects of the market and its key segments over the period between 2016 and 2024. The report presents a thorough analysis of the key factors, such as drivers, challenges, past and present trends, competition, and regulatory landscape of the market, which are expected to have a notable influence on the future growth prospects of the market over the said period.
The report includes rich qualitative and quantitative data pertaining to these factors, gathered with the help of several primary as well as secondary research methodologies over the past few years. The report also includes an analysis of various market elements with the help of research methodologies such as Porter’s five forces analysis, which helps gauge the intensity of the key forces defining the competitive intensity and thus the attractiveness of a market for potential entrants.
The report also presents a detailed overview of the key micro and macroeconomic factors expected to have a wide-ranging impact on the market’s development over the period between 2016 and 2024. The report, with all this data, makes for a data repository that can aid companies in the market to formulate optimal growth strategies for promising returns in the field of single-use bioreactors.
Global Single-use Bioreactors Market: Drivers and Restraints
The significantly rising cost pressures in the pharmaceutical industry and the increasing demand for new drug varieties to serve a vast number of new and untreated disease categories are compelling companies to reevaluating their operational and manufacturing processes. The use of single-use bioreactors is chiefly driven due to these pressures and an increasing number of pharmaceutical companies are adopting disposable bioreactors to speed-up the introduction of new product lines.
The market is witnessing significant developments in terms of materials, variety, and flexibility of bioreactors to be used across a large set of culture mediums. Several varieties of single-use technologies such as mixers, disposable vessels, and bioreactor bags have started to proliferate the market and an increasing number of manufacturers are venturing into to field to exploit the vast growth opportunities.
Global Single-use Bioreactors Market: Geographical and Competitive Dynamics
In terms of geography, the market for single-use bioreactors is presently dominated by North America and Europe owing to the presence of a large number of some of the world’s leading biopharmaceutical companies. In the near future, the market is also expected to witness promising growth opportunities in regions such as Asia-Pacific and Latin America as many international biopharmaceutical companies operate in these regions through large-scale manufacturing facilities in these regions.
The global market for single-use bioreactors market has become highly dynamic in the past few years, chiefly owing to new entrants and vast positive developments in the area of product variants. Some of the key vendors presently operating in the market are Sartorius Stedim Biotech, GE Healthcare, PBS Biotech, Thermo Fisher Hyclone, Merck Millipore, Xcellerex, and Cellexus Limited.
Posted by at No comments:
Labels: , , ,

Essential Tremor Treatment with Ultrasound Market: Business Challenges, Emerging Technologies & Competitive Landscape

Essential Tremors (ET) also known as benign tremor, familial tremor, and idiopathic tremor. Essential tremors are involuntary trembling in one or more parts of body. The cause of tremors is due to problems in parts of the brain that controls muscle in the body or in specific parts of the body, such as hands. It can also affect arm, head, eyes, face, vocal cord, trunk, and legs. Most tremors occur in the hands, which can impair patient’s ability to eat, shave, write, and perform household activities and functions in the workplace. Essential tremors are most common in people who are middle-aged and older, but anyone can suffer from this disorder. Treatment to relieve this disorder depends on their causes. Tremors can be treated by medicines or surgical procedure to improve muscles control. Essential tremors are not life threatening. However, they can be a cause of embarrassment and make it difficult to perform daily tasks. Treatment options for essential tremors are medication, deep brain stimulation (DBS), and thalamotomy. Medication is first line treatment option for essential tremors. Focused ultrasound is a completely non-invasive treatment of thalamotomy, which could be more effective than other methods. Focused ultrasound is performed when patients are awake and involves no anesthesia, no incision in the scalp, and no burr holes through skull or insertion of electrode through brain during the treatment. This provides a measure of safety because they can respond during the procedure. During focused ultrasound therapy, targeted cell in the thalamus are visualized in real time imaging. Focused beam of acoustic energy are used to heat and destroy target cells without impairing adjoining tissue.
Essential tremors treatment with ultrasound market is supposed to be driven by factors such as increase in age related neurological disorder. FDA approvals for clinical trials and huge inflow of new players entering the market is leading can be factor for growth of essential tremor treatment market with ultrasound. Advanced technology, improved clinical outcomes and awareness regarding consumer preferences are factors that drive the growth of essential tremor treatment with ultrasound market. It is a non-invasive treatment that facilities patients to recover rapidly and perform day today task. Temporary sensory disturbances or lack of stability after treatment has been documented in can impact the growth of the market. Factor such as possibility of damage of other tissues can also restrain the growth of the essential tremor treatment with ultrasound market.
The global market of essential tremors treatment with ultrasound is segmented on the basis of indication end users and geographical region.
  • Segmentation by Indication
    • Head
    • Trunk
    • Upper Extremity
    • Lower Extremity
  • Segmentation by End User
    • Hospitals
    • Ambulatory Surgical Centers
  • Segmentation by Region
    • North America
    • Latin America
    • Europe
    • Asia Pacific
    • Middle East & Africa
According to American Academy of Neurology (AAN) conference report published in 2016 by Samantha J. Peterson, estimate that patients who have been treated with ultrasound for essential tremors have acknowledge around 50% development after 3 months and observed around 40% progress after a 10 months. International Essential Tremor Foundation estimated that 3% of population or approximately 10 million individuals in U.S. are affected by essential tremors in 2015. Based on indication the global market of essential treatment with ultrasound are segmented as Head, Trunk, Upper Extremity, and Lower Extremity. The Upper Extremity segment is expected to dominate the global market of essential tremor treatment with ultrasound. On the basis of end user, essential tremor treatment with ultrasound market is classified as Hospitals and Ambulatory Surgical Center. In this segment, ambulatory surgical center is expected to contribute maximum to the market share.
On the basis of regional presence, the global Essential Tremor Treatment with Ultrasounds market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to dominate the market of essential tremors with ultrasound due to factors such as sophisticated healthcare infrastructure and increasing awareness of patients and healthcare professionals. After North America, the essential tremor treatment with ultrasound market is expected to be dominated by Europe and Asia. Asia Pacific is the fastest growing region for essential tremor treatment market due to improving healthcare facility. In Asia Pacific region, developing countries such as India and China are expected to offer good opportunities for the global Essential Tremor Treatment with Ultrasound market due to rising expenditure levels for significant growth.
Posted by at No comments:
Labels: , ,

Colorectal Cancer Treatment Market - New Market Research Report Announced; Global Industry Analysis 2016 - 2024

Colorectal cancer is cancer that starts in the colon or rectum. The colon and the rectum are parts of the large intestine, which is the lower part of the body’s digestive system. The colon absorbs water and nutrients from the food and stores waste matter (stool). Stool moves from the colon into the rectum before it leaves the body. Colorectal cancer often begins as a growth called a polyp, which may form on the inner wall of the colon or rectum. Some polyps become cancer over time. Finding and removing polyps can prevent colorectal cancer. During digestion, food moves through the stomach and small intestine into the colon. Most colorectal cancers are adenocarcinomas (cancers that begin in cells that make and release mucus and other fluids). Some of the commonly seen symptoms of colorectal cancer are blood in the weight loss, fatigue, stool, and irregular bowel movements. Colorectal cancer is a result of uncontrolled cell growth that occurs in the appendix, colon, and the rectum region.
According to American Cancer Society, in United States when men and women are considered individually colorectal cancer is the third prominent cause of cancer-related mortality, and the second prominent cause when both sexes are combined. With the use of fecal occult blood tests and colonoscopies, which check for blood in the stool the deaths from colorectal cancer have decreased. Ageing, fatty diet, excessive consumption of red meat or alcohol, male gender, obesity, smoking are the most commonly observed causes for colorectal cancer. Most colorectal cancers originate as a polyp, a growth in the tissue that lines the internal surface of the rectum or colon and it is common in people older than 50 years of age, and most are not cancer.
The global market for colorectal cancer market is segmented on basis of treatment options, Colorectal Cancer Stage, end user and geography:
  • Segmentation by Diagnosis
    • Fecal Occult Blood Tests
    • Stool DNA test
    • Sigmoidoscopy
    • Colonoscopy
    • Virtual Colonoscopy
    • Double-contrast Barium Enema
    • Others
  • Segmentation by Treatment Options
    • Surgery
    • Radiation therapy
    • Chemotherapy
    • Targeted therapy
    • Others
  • Segmentation by Colorectal Cancer Stage
    • Stage 0
    • Stage I
    • Stage II
    • Stage III
    • Stage IV (Metastatic)
Increasing adoption of western diet which are high in fat and low in fiber is expected to boost the growth of colorectal cancer market over the forecast period. Based on diagnosis, colorectal cancer are classified as fecal occult blood tests, stool DNA test, sigmoidoscopy, colonoscopy, virtual colonoscopy, double-contrast barium enema, others.
Based on treatment option, colorectal cancer are classified as surgery, radiation therapy, chemotherapy and targeted therapy. Surgery remains the most effective treatment for colorectal cancer. Radiation therapy reduces the chance of cancer spread or recurrence and is effective as additional or adjuvant therapy either before or after surgery. The segment is expected to grow rapidly over the forecast period due to increasing technological advancement and increasing awareness.
Based on colorectal cancer stage, colorectal cancer has been segmented into stage 0, stage I, stage II, stage III, and stage IV (metastatic). According to National Cancer Institute, in 2016, an estimated 134,490 people in the United States will be diagnosed with colorectal cancer and 49,190 people will die from it. In general, stages 0, I, II, and III are often curable with surgery. Patients with stage II and III rectal cancer receives radiation therapy with chemotherapy either before or after surgery. Patients with stage III colorectal cancer, and some with stage II, receive chemotherapy after surgery to increase the chance of eliminating the disease. Stage IV is not often curable, but it effects can be reduced, and the growth of the cancer and the symptoms of the disease can be managed.
On the basis of regional presence, global colorectal cancer market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global colorectal cancer market for due to aging population. Due to increase in screening of colorectal cancer and changes in some risk factors such as a decline in smoking and consumption of alcohol is decreasing the rate of new colorectal cancer cases and deaths among adults aged 50 years and above.
Some of the major players in global colorectal cancer market are Hoffmann La Roche, Debiopharm Group, Merck KGaA, Vaccinogen BD, AEterna Zentaris, and Keryx Biopharmaceuticals, Inc., etc.
Posted by at No comments:
Labels: , , ,

Medical Gas Analyzers Market Size & Forecast 2016 to 2024

Medical gas analyzers are instruments used for determining and measuring qualitative and quantitative composition of pure medical gases, or mixtures of medical gases. Medical gases used in hospitals and other healthcare settings mainly comprise of medical air, oxygen, carbon di-oxide, nitrogen and nitrous oxide. Medical gas analyzers include equipment and instruments such as vacuum systems, regulators, flow meters, monitoring systems (such as alarms and monitors), fluidics (valves, pumps, tubing), sealing solutions, and concentrators. These instruments analyze the concentration of medical gases and their mixtures, such as oxygen-nitrous oxide, etc., along with their purities, and presence of any impurities such as water vapors, and other organic and inorganic impurities, in the medical gases. Medical gas analysis is becoming an important and integral part of patient monitoring, safety, and diagnosis along with patient treatment. The application of medical gas analysis is gaining momentum and is being implemented in various healthcare facilities worldwide.
Technological advancements in the medical gas analyzers market, with new and advanced products coming through the pipeline of major players, along with growing awareness of patient safety and monitoring among the healthcare service providers around the world, especially in the emerging economies, are some of the key drivers that are fuelling the growth of medical gas analyzers market. However, changing guidelines regarding calibration standards of analyzers, increasing burden of reimbursements on governments resulting in various organizations declining reimbursements for respiratory therapies, are some factors that are restraining the growth of medical gas analyzers in the global market
The global market for medical gas analyzers is segmented on basis of equipment, applications, end user and geography:
  • Segmentation by Equipment
    • Vacuum systems
    • Regulators
    • Flow meters
    • Monitoring systems
    • Concentrators
    • Accessories (Outlets, Hose, etc.)
  • Segmentation by Application
    • Respiratory Diseases
    • Cardiovascular Diseases
    • Anesthesia
    • Medical Imaging
    • Cryotherapy
    • Laboratory Use
    • Others
  • Segmentation by End User
    • Hospitals
    • Ambulatory Surgery Centers
    • Diagnostic Centers
    • Academic Research Institutes
Based on equipment, vacuum systems contributed the largest share of the medical gas analyzers market in 2015, followed by monitoring systems .Based on application type, cardiovascular diseases segment dominated the global medical gas analyzers market. According to the American Heart Association, in 2015, cardiovascular disease is the leading global cause of deaths, with around 17.3 Mn deaths per year globally, followed by respiratory diseases. In 2013, according to World Health Organization (WHO), Chronic Obstructive Pulmonary Disorders (COPD) resulted in around 3 Mn deaths worldwide. Growing number of geriatric population, has resulted in an increase in cardiovascular diseases, respiratory disorders, and other age related diseases. Also, increasing air pollution and number of smokers, are some factors responsible for the growth of the global medical gas analyzers market.
On the basis of regional presence, global medical gas analyzers market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America is expected to lead the global medical gas analyzers market for due to advanced healthcare infrastructure, higher adoption of technologies, and availability of reimbursement policies. Asia Pacific market is anticipated to grow at the fastest growth rate during the forecast period, owing to factors such as increasing air pollution especially in countries such as China, Japan, and India. Growing medical tourism industry in these countries, is likely to attract patients from across the world.
Some of the major players in global medical gas analyzers market are Air Products and Chemicals, Inc., The Linde Group, Air Liquide, Matheson Tri-Gas, Airgas, GCE Holding AB, Messer Group Gmbh, Praxair, Inc., Taiyo Nippon Sanso Corp., Novair Medical, among others. New technologically advanced products and systems being launched in the global market, along with expansion in the emerging markets, and greater focus on patient care and monitoring, have been the major strategies adopted by major players in the global medical gas analyzers market.
Posted by at No comments:
Labels: , , ,

Lysosomal Acid Lipase Deficiency Treatment Market Offering High-growth Opportunities for Market Players

The December 2015 U.S. FDA approval of a breakthrough drug in the LAL deficiency treatment market, has set the ball rolling for tremendous potential in the growth of this rare-disease market. Lysosomal Acid Lipase (LAL) Deficiency, also known as Cholesterol Ester Storage Disorder (CESD), Wolman’s Disease or LAL deficiency, is an inherited, ultra-rare genetic disease affecting children as well as adults. Lysosomal acid lipase (LAL) is responsible for the hydrolysis of cholesterol esters and triglycerides. Patients with LAL deficiency have no or little LAL enzyme activity which results in the accumulation of fats within various body cells that leads to high cholesterol and triglycerides, and a very low HDL-cholesterol level. There are two main types of LAL disorder: early onset Wolman Disease and late onset CESD. Wolman disease is very rare, with an incidence of less than one in 100,000 live births. CESD is a less severe, later-onset disorder which can occur in adults at any stage in life, having an incidence of about one in 25 per million births. While Wolman disease is a relatively occurrence, the infants affected with it usually die within the first year of birth after experiencing growth failure, liver fibrosis, and cirrhosis. In late onset LAL deficiency, the accumulation of cholesteryl esters and triglycerides in blood vessels, vital organs, and other tissues of adults, results in progressive and multiple-organ damage which includes fibrosis, cirrhosis, liver failure, accelerated atherosclerosis, and cardiovascular disease. Since LAL disease has symptoms similar to many other diseases, for instance, heart disease, it is often misdiagnosed. The disease in its late onset form does not affect everyone equally and thus symptoms can vary from person to person, often manifesting as mild symptoms which consequently also makes the disease underdiagnosed worldwide. The biggest factor that shall drive the market is that currently, apart from a recently approved drug by U.S. FDA known as Kanuma (sebelipase alfa), there is no approved treatment available for the disease. Thus, tremendous business opportunity lies in the investment of finding therapies for treatment in this market. Lack of awareness regarding disease diagnosis and untimely treatment due to ignorance of symptoms may restrain the growth of the market.
The global market for lysosomal acid lipase (LAL) deficiency is segmented on basis of type of therapy, type of drug, disease indication and geography:
  • Segmentation by Type of Therapy (no. of surgeries)
    • Liver Transplant
    • Hematopoietic Stem Cell Transplant
  • Segmentation by Type of Drug
    • Statins and other dyslipidemia drugs
    • Sebelipase alfa (Kanuma)
  • Segmentation by Disease Indication
    • Wolman Disease
    • Cholesteryl ester storage disease (CESD)
LAL deficiency is a chronic progressive genetic metabolic disease associated with substantial morbidity as well as premature mortality. It is an ultra-rare disease, which is defined as a disease that affects fewer than 20 patients per one million of the general population. The current management practice for the disease involves taking lipid lowering medications such as statins, to overcome symptoms of lipid accumulation. However, progression of the disease often necessitates the patient to undergo a liver transplant. The market for lysosomal acid lipase (LAL) deficiency is segmented based on number of surgeries: for liver transplant and for hematopoietic stem cell transplant. A liver transplant may give LAL patients respite from liver failure, but it does not tackle the underlying cause of the disease and may not stop disease progression in extra-hepatic organs, which include the heart and kidneys. However, it is still an option for patients who wish to increase chances of survival. Although hematopoietic stem cell transplant has been performed in a few infants with lysosomal acid lipase (LAL) deficiency, it has been associated with complications and the long term outcomes are unknown. Thus, the liver transplant segment shall witness more number of surgeries during the forecast period compared to the hematopoietic stem cell transplant segment.
Based on disease indication, sebalipase alfa segment is expected to contribute largest share in global lysosomal acid lipase (LAL) deficiency treatment market due to it being the only approved mainstay treatment for the disease. Statins although helpful in symptom management for lysosomal acid lipase (LAL) deficiency, are not effective in completely preventing the progression of the disease, resulting in their estimated lower share in the market compared to sebalipase alfa. Moreover, the value garnering segment would be sebalipase alfa due to its higher cost of treatment and also being the preferred treatment due to it being the only approved drug for this indication. On the basis of disease indication, the market has been segmented into wolman disease and cholesteryl ester storage disease (CESD). The market for CESD is anticipated to be higher due to comparatively higher need in this segment.
On the basis of regional presence, global lysosomal acid lipase (LAL) deficiency treatment market is segmented into five key regions viz. North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America and Europe are expected to lead the global lysosomal acid lipase (LAL) deficiency treatment market due to high prevalence of this rare disease.
Some of the major players in global lysosomal acid lipase (LAL) deficiency treatment market are Alexion Pharmaceutical Inc., AstraZeneca plc., Merck & Co., Inc., Pfizer, Inc. and Teva Pharmaceutical Industries Ltd.
Posted by at No comments:
Labels: , ,

Ingestible Sensors Market grows with rising awareness among the general population

Ingestible sensors is an innovative technologically advanced product of digital medical industry. Ingestible Sensors are pills that have the ability to detect various bodily functions and activities, medication check, heart rate and blood pressure. It has three components sensors, data recorder, and software. These ingestible sensors help patients receive real-time information and address the unaware issues which are sometimes not answered by doctors. The ingestible sensor works as soon as the sensor enabled pill is consumed. This pill sends signals to the patch, which helps to detect the duration in which the pill was consumed. As the data is recorded, the information is being displayed with the help of linked discover application that can be downloaded on a mobile device. With the help of this application patients can analyze the data and work accordingly, this helps them to decide if there is any need to visit a healthcare provider, taking medication on time and others. The ingestible sensors market is driven by increasing prevalence of chronic conditions and advancement in technology.
According to the Centers for Disease and Control of Infection, there are more than one-third (36.5%) of U.S. adults that suffer from obesity. Obesity-related conditions comprise of diabetes, heart disease, stroke, certain types of cancer, and some of these are leading causes of preventable death. IN U.S., the incidence rate of chronic conditions such as heart disease, cancer, type 2 diabetes, obesity, arthritis and others are among the most common of all health problems. In 2012, 117 Mn people suffered from one or more chronic health conditions. Moreover due to benefits such as cost-effective products, growing population of immune compromised individuals and others, the physician is prescribing these products. The patient education program is conducted by government and companies for creating the awareness among the general population. However Ingestible sensors market has some restraints such as low adoption for these products may hinder the growth of the Ingestible sensors market.
The Global Ingestible sensors market is segmented on the basis of sensor type, application, end user and regional presence:
  • Segmentation based on Sensor Type:
    • Temperature sensor
    • Pressure sensor
    • pH sensor
    • Image sensor
  • Segmentation based on Application
    • Medical/Healthcare
    • Sports & fitness
    • Others
  • Segmentation based on end user
    • Research Institutes
    • Pharmaceutical companies
    • Healthcare providers
    • Sports & Physical Fitness institutions
Increasing sedentary lifestyle among population leading to rising in the incidence of chronic conditions is expected to boost the Ingestible sensors market over the forecast period. Also rising awareness among the general population and rise in disposable income is expected to drive the Ingestible sensors market during the forecast period.
Geographically the Ingestible sensors market is segmented into five key regions: North America, Latin America, Europe, Asia-Pacific and MEA region.
North America followed by Europe is dominating the Ingestible sensors market as a high incidence of gastroparesis cases, and favorable reimbursement options provided by governments and insurance companies which have provided the platform for these products. In Asia Pacific region the Ingestible sensors market is expected to deliver significant growth due to the high pool of geriatric population in this region and growing economy which is expected to further fuel market demand. Moreover, the Ingestible sensors market is expected to become highly competitive due to the potential entrants in the market by the end of forecast period.
Some of the major companies in the Ingestible sensors market are HQ, Inc., Proteus Digital Health, Inc., CapsoVision, Inc., Given Imaging, Ltd., Medimetrics Personalized Drug Delivery B.V., Olympus Corporation, and others. Key strategy used by Proteus Digital Health, Inc is utilizing innovative approach for improving health outcomes for patients and for patients that are facing challenges managing their medications.
Posted by at No comments:
Labels: , , ,

Resorbable Implants Market driven by rising geriatric population

A man made medical device which supports, enhances or replaces the existing, damaged or missing biological structure, by implanting it into the human body is called as implants. There are several types of implants available in the market with a wide range of specialties. One of which is Resorbable implant. These implants have special and distinguished property. Such implants are biologically assimilated into the body slowly and is not required to be removed after a stipulated time. They have several dental, orthopedic and vascular applications. Resorbable implants are the prosthetic in nature and are used to regularize the physiological function in the human body. The worldwide increasing life expectancy and declining mortality rate have resulted in increased population of the age group above 60 years. Hence globally the geriatric population is growing at a faster rate than any other age group. The demand of such a population is fast, safe and effective treatment for their age related medical problems. Several applications of such implants into the orthopedic and dental field has also triggered the demand and usage owing to appreciable patient outcome. This has gripped the consideration of resorbable-implant companies to invest into such a market. Also key players are keenly interested in developing and commercializing the implants that are more cost effective and which will fulfill the geriatric patient demand.
The dental treatment including the usage of implants has a wide range of medical conditions like reconstruction of craniomaxillofacial bone due to trauma and facial prosthetic to correct the facial deformities, Mandibular fixation etc. The orthopedic treatment with the usage of resorbable implants includes Hand surgery, Bankart procedure, Trauma, Scaphoid fractures, Ankle ligament lesions.
Examples of resorbable implants are resorbable stent, resorbable mesh, resorbable band, resorbable scaffolds, and resorbable tethers. Resorbable Stents are usually used in cardiac and vascular indication whereas resorbable mesh are used in general surgeries for wound healing. Resorbable bands scaffolds and tethers have orthopedic applications.
The material most commonly used in resorbable implants are polyglycolic acid, polylactic acid, polydiaxonone, poly-L-lactic acid, poly-D-lactic acid, polycaprolactone, poly beta hydroxybutyrate. Polyglycolic acid and Polylactic acid are most popular amongst the orthopedic implants due to its unique mechanical and biocompatible property which is mandatory for its application. The upcoming materials used in resorbable implants are poly-L-lactic acid and poly-D-lactic acid. The L isomer is not only biologically inert but also biodegradable and biocompatible which helps to initiate the neocollagenesis process. As a result collagen builds up at the site of injection over the time and the poly-L-lactic acid microparticles is metabolized to carbon dioxide and water and expelled through respiratory system. These materials are usually used in the screws and plates used in orthopedic indications.
Several factors which are majorly driving the growth of resorbable implants market are growing concern for chronic diseases, rising geriatric population, growing disposable incomes and high level of healthcare .In addition, increasing areas of application mainly in medical and dental streams will contribute to the market growth. The pipeline and the future advancement in resorbable implants is anticipated to have a robust market growth. However time consuming approval procedures of implants by regulatory bodies, reimbursement issues and high cost of treatment would hamper the growth of resorbable-implants market.
The global resorbable implants market is segmented based on product type as Resorbable Stent, Resorbable Mesh, Resorbable Band, Resorbable Scaffolds, and Resorbable Tethers.
The global resorbable implant market is segmented based on material type as Polyglycolic acid, Polylactic acid, Polydiaxonone, Poly-L-Lactic acid, Poly-D-Lactic Acid, Polycaprolactone, Poly beta Hydroxybutyrate.
The global resorbable implants market is segmented based on application as Orthopedic Surgeries, dental Surgery, vascular Surgery and General Surgery.
The global resorbable implants market is segmented based on end user as Hospitals, Ambulatory Surgical Centers, and Specialty Clinics.
Depending on geographic region, resorbable implants market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
By resorbable implants type, stents and mesh are the choice of implants among the relatively limited resorbable implants that are approved in the market. The bands, scaffolds and tethers are popular amongst the orthopedists and dentists and holds noticeable share due to its easy availability and lower cost.
North America region holds the largest share of the global resorbable implant market, in terms of revenue due to the stronger health care infrastructure and considerable pool of the key manufacturers. Following North America Europe is the second largest resorbable implants market owing to technological advancement in the region. In addition, high disposable income and increase in geriatric population in developing countries like India and China, are expected to drive the growth resorbable implants market in Asia.
Key companies operational in resorbable implants market are Proxy Biomedical Ltd, KLS Martin LP., Bionx Implants Inc., Tornier, Inc., Degradable Solutions AG, Integra Life Sciences Corporation, Johnson & Johnson Services, Inc.,
Posted by at No comments:
Labels: , , ,
Subscribe to: Posts (Atom)